Mitochondrial superoxide generation induces a parkinsonian phenotype in zebrafish and huntingtin aggregation in human cells. by Pinho, Brígida R et al.
1Mitochondrial superoxide generation induces a parkinsonian phenotype in 
zebrafish and huntingtin aggregation in human cells 
Brígida R. Pinho1, Sara D. Reis1, Richard C. Hartley2, Michael P. Murphy3, Jorge M. A. 
Oliveira1,4*
1REQUIMTE/LAQV, Department of Drug Sciences, Pharmacology Lab, Faculty of 
Pharmacy, University of Porto, Portugal
2WestCHEM Scholl of Chemistry, University of Glasgow, UK 
3MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge CB2 0XY, UK
4Consortium for Mitochondrial Research (CfMR), University College London, Gower 
Street, WC1E 6BT, London, UK 
*Corresponding author:
Jorge M. Ascenção Oliveira
Departamento de Ciências do Medicamento, Laboratório de Farmacologia, Faculdade de 
Farmácia, Universidade do Porto.
Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
Tel. +351 220428610
Email: jorgemao@ff.up.pt 
2Abstract
Superoxide generation by mitochondria respiratory complexes is a major source of 
reactive oxygen species (ROS) which are capable of initiating redox signalling and 
oxidative damage. Current understanding of the role of mitochondrial ROS in health and 
disease has been limited by the lack of experimental strategies to selectively induce 
mitochondrial superoxide production. The recently-developed mitochondria-targeted 
redox cycler MitoParaquat (MitoPQ) overcomes this limitation, and has proven effective 
in vitro and in Drosophila. Here we present an in vivo study of MitoPQ in the vertebrate 
zebrafish model in the context of Parkinson’s disease (PD), and in a human cell model of 
Huntington’s disease (HD). We show that MitoPQ is 100-fold more potent than non-
targeted paraquat in both cells and in zebrafish in vivo. Treatment with MitoPQ induced 
a parkinsonian phenotype in zebrafish larvae, with decreased sensorimotor reflexes, 
spontaneous movement and brain tyrosine hydroxylase (TH) levels, without detectable 
effects on heart rate or atrioventricular coordination. Motor phenotypes and TH levels 
were partly rescued with antioxidant or monoaminergic potentiation strategies. In a HD 
cell model, MitoPQ promoted mutant huntingtin aggregation without increasing cell 
death, contrasting with the complex I inhibitor rotenone that increased death in cells 
expressing either wild-type or mutant huntingtin. These results show that MitoPQ is a 
valuable tool for cellular and in vivo studies of the role of mitochondrial superoxide 
generation in redox biology, and as a trigger or co-stressor to model metabolic and 
neurodegenerative disease phenotypes. 
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31. Introduction 
Reactive oxygen species (ROS) were originally characterized as cell-damaging by-
products of biological reactions. There is now compelling evidence that ROS also 
participate in physiological signaling, regulating redox-dependent switches in proteins 
that govern proliferation, metabolism, gene transcription, inflammation and ageing 
(Drazic and Winter, 2014; Holmstrom and Finkel, 2014; Sena and Chandel, 2012). 
Superoxide produced by mitochondrial respiratory complexes is a major source of ROS, 
involved in signaling to other cellular compartments and in oxidative damage (Angelova 
and Abramov, 2016). Available strategies to increase mitochondrial superoxide include 
respiratory complex inhibitors, which disturb the membrane potential and ATP synthesis 
(Murphy, 2009), and non-targeted redox cyclers, which lead to substantial superoxide 
production outside mitochondria (Cocheme and Murphy, 2008), thereby confounding 
data interpretation. Thus, the current understanding of the pathophysiological role of 
mitochondrial superoxide has been limited by the lack of strategies to selectively increase 
its generation in cells and in vivo (Holmstrom and Finkel, 2014).
MitoParaquat (MitoPQ) is a recently developed molecule comprising the redox cycler 
paraquat conjugated to a mitochondria-targeting triphenylphosphonium lipophilic cation. 
MitoPQ accumulates in energized mitochondria and produces superoxide by redox 
cycling at complex I. It was previously shown in vitro that MitoPQ increases 
mitochondrial superoxide production in cells, and disturbs cardiac function in the isolated 
perfused mouse heart (Robb et al., 2015). There is currently limited information on the in 
vivo effects of MitoPQ, particularly in disease models. In vivo, MitoPQ was previously 
tested only in flies (Drosophila melanogaster), where it was found to reduce lifespan, 
without further functional or behavioral analyses (Robb et al., 2015). Here we have 
performed the first in vivo characterization of the effects of MitoPQ in a vertebrate model, 
the zebrafish (Danio rerio). We also assessed the usefulness of MitoPQ in the context of 
neurodegenerative disease modeling in cells. 
Zebrafish is well-suited for in vivo drug screening given its advantages, including 
larval transparency (allowing non-invasive studies of cardiac function), reduced size 
(facilitating behavioral evaluation), and high genetic and physiological homology to 
mammals (Stewart et al., 2014). The zebrafish is increasingly used to study 
neurodegenerative disorders (Pinho et al., 2016; Veldman et al., 2015) and associated 
processes such as mitochondrial dysfunction (Artuso et al., 2012; Pinho et al., 2013) and 
4oxidative stress (Fang and Miller, 2012; Gauron et al., 2013; Massarsky et al., 2017; 
Muller et al., 2018). 
Here we investigate in vivo mitochondrial superoxide generation by MitoPQ in 
zebrafish.  Complementing prior evidence that MitoPQ selectively generates superoxide 
within mitochondria (Robb et al., 2015), we show here the higher potency of MitoPQ vs. 
paraquat in cells and in zebrafish. We further show that MitoPQ induces a parkinsonian 
phenotype in zebrafish, with decreased spontaneous movement and brain tyrosine 
hydroxylase levels. We also tested MitoPQ in a Huntington’s disease cellular model 
where it increased mutant huntingtin (mHtt) aggregation. These results support MitoPQ 
as a useful tool for investigating superoxide production in pathology in animal and cell 
models of disease.   
2. Material and Methods
2.1. Drugs, solvents and solutions
MitoPQ was synthesised as previously described (Robb et al., 2015). Culture media and 
supplements were from Gibco. Paraquat, N-acetyl-L-cysteine (NAC), desipramine, 
rotenone, myxothiazol, antimycin A, oligomycin B, and all other drugs or reagents were 
from Sigma-Aldrich, unless otherwise stated. MitoPQ, rotenone and oligomycin stock 
solutions were prepared in dimethyl sulfoxide (DMSO), whereas those from desipramine, 
paraquat, and NAC were prepared in water. Myxothiazol and antimycin stock solutions 
were prepared in methanol. Experiments in zebrafish larvae were performed with 0.1 – 
0.5% DMSO. Experiments in U2OS cells were performed in presence of 0.1 - 0.5% 
DMSO or 0.1% methanol.  Control treatment conditions contained the same amount of 
solvent (DMSO or methanol) as the respective drug treatment conditions.
2.2. Zebrafish maintenance and drug treatments 
Adult wild-type zebrafish (Danio rerio) or larvae were maintained at 28 ± 1ºC with 
14h:10h light:dark cycles and handled for egg production as we previously described 
(Pinho et al., 2016; Pinho et al., 2013). Fertilized eggs were kept in autoclaved water 
containing 1 µM methylene blue until 3 days post fertilization (dpf). At 3 dpf, hatched 
5larvae without detectable abnormalities were randomly distributed into multi-well plates, 
containing autoclaved water and exposed to treatments (MitoPQ, paraquat, NAC, 
desipramine, or solvent). In all experiments, larvae were imaged daily with a 
stereomicroscope to assess viability. Dead larvae were removed, and half volume was 
replaced with freshly prepared treatment solutions (Pinho et al., 2016). For survival and 
movement experiments, larvae were exposed to drugs in 24-well plates (5 larvae/ 500 µL/ 
well), while to assess cardiovascular function, larvae were exposed to drugs in 96-well 
plates (1 larvae/ 200 µL/ well). In population assays, such as quantification of adenosine 
nucleotides and dot-blot, as well as for immunofluorescence, larvae were exposed to 
drugs in 12-well plates (15-30 larvae/ 1mL/ well). 
2.2.1. Cardiovascular function
At 5 and 6 dpf, larvae were anaesthetized with 0.8 M tricaine methanesulfonate and their 
heartbeats recorded for 30s, at 10x magnification in a customised Nikon-Prior-
Hamamatsu (NPH) Imaging System, composed by an inverted microscope (Eclipse 
TE300, Nikon), a motorized stage (ProScan, Prior), a CCD camera (ORCA-ER, 
Hamamatsu), and a monochromator (Polychrome II, Photonics), all controlled by the 
open source software Micro-Manager (v. 2.0; https://micro-manager.org). Videos were 
captured at 30 frames per second (fps) and processed with ImageJ 
(https://imagej.nih.gov/ij/) for assessing atrioventricular coordination and heart rate. 
2.2.2. Adenine nucleotides and energy charge 
Nucleotide extraction was performed at 5 and 6 dpf, as we previously described (Pinho 
et al., 2016), but now using a Precellys 24 homogenizer (Bertin Technologies) at 6800 
rpm (3 x 20s, CK28 beads). ATP, ADP and AMP were quantified using HPLC (reversed-
phase column; 2504.6mm Luna 5µm C18(2) 100Å; Phenomenex) with a diode-array 
detector (Agilent 1100 series), measuring 260 nm absorbance. Energy charge was 
calculated with the formula: ([ATP]+0.5[ADP])  ([ATP]+[ADP]+[AMP]) (Torrecilla et 
al., 2001).
2.2.3. Behavioural evaluation
6Measurements of spontaneous swimming and sensorimotor reflexes were performed at 5 
dpf, as we previously described (Pinho et al., 2016). Briefly, individual larvae in 6-well 
plates were recorded for 10 min at 28  1 ºC with a HD digital camera (C525, Logitech). 
Videos were processed with iWisoft (www.iwisoft.com/videoconverter) and ImageJ to 
extract time and spatial coordinates. Calculations were automated in customised 
spreadsheets (Excel, Microsoft) to derive movement parameters: distance (cm), 
movement speed (distance  time in movement; mm/s), and initiations. After the 
spontaneous swimming, each larva was tested for reflexes by gently touching with a 
micropipette tip in the head and in the tail. Immediate swimming after touch was scored 
as a positive response. Head and tail touches were alternated, spaced by 30 s, and the 
procedure repeated 10 times for each larva. 
2.2.4. Quantification of protein carbonyl groups
Protein extraction was performed at 5 dpf by sonication of 45 larvae in ice-cold lysis 
buffer (250 mM sucrose; 20 mM HEPES; 3 mM EDTA, pH=7.5) supplemented with a 
protease inhibitor cocktail (Fisher Scientific). After 3 freeze-thaw cycles, lysates were 
centrifuged at 300g (10 min, 4 ºC) and carbonyls quantified in the supernatant. Protein 
was quantified according to Bradford method and carbonyl derivatization was performed 
as previously described (Levine et al., 1994), with minor modifications. Briefly, 200 µL 
of protein extract containing 20 µg protein were incubated with 200 µL of 12% sodium 
dodecyl sulfate and 400 µL of 20 mM 2,4-dinitrophenylhydrazine hydrochloride (TCI 
Europe) for 30 min in the dark. After neutralization with 300 µL of 2 M Tris with 18% 
-mercaptoethanol, samples containing 1µg of protein were spotted on a nitrocellulose 
membrane (Bio-Dot Microfiltration Apparatus, Bio-Rad). Membranes were blocked for 
1 h with 5% bovine serum albumin in PBST (phosphate buffer solution with 0.05% 
Tween 20), and incubated with anti-dinitrophenol antibody (MAB2223, 1:1000, Sigma-
Aldrich; 1 h). After washing with PBST, membranes were incubated with secondary 
antibody (G-21040, 1:4000; Life Technologies; 1 h), and imaged using a 
Chemiluminescent kit (Novex ECL, Life Technologies) and a ChemiDoc MP (Bio-Rad). 
Coomassie staining was used for loading control. Densitometric analyses were performed 
with Image J.
72.2.6. Immunofluorescence 
At 5 dpf, larvae were fixed (4% paraformaldehyde, overnight at 4ºC) and processed for 
immunofluorescence as we previously described (Pinho et al., 2016). Primary antibodies: 
anti-acetylated--tubulin (T6793, Sigma-Aldrich; 1:1000) or anti-tyrosine hydroxylase 
(TH) (MAB318, Merck Millipore; 1:500) overnight at 4 ºC. Secondary antibody: anti-
mouse AlexaFluor-488 (A-11029, Life Technologies) overnight at 4 ºC. Larvae mounted 
in Glycergel medium (DAKO) were imaged in the aforementioned NPH Imaging System. 
For intensity comparisons, non-saturated images were acquired with identical equipment 
settings. The mean intensity of immunofluorescence was quantified after background 
subtraction using ImageJ. 
2.3. U2OS cell maintenance
Human U2OS cells have been previously used to study mHtt aggregation (Bersuker et 
al., 2013). These cells are advantageous for their high transfection efficiencies, and also 
for imaging studies (large, flat cells with clearly-defined nuclear and cytosolic 
compartments), explaining their widespread use, including in neurodegenerative disease 
contexts (Becker et al., 2017; Bersuker et al., 2013; Rasool et al., 2018). Here, U2OS cells 
(ATCC) were cultured in either glucose media (glycolytic conditions) or galactose media 
(oxidative phosphorylation – OXPHOS – dependent conditions). Glucose media was 
composed by Dulbecco’s Modified Eagle’s Medium (DMEM) with low glucose 
supplemented with 10% foetal bovine serum (FBS) and penicillin/streptomycin. 
Galactose media was composed by DMEM without glucose supplemented with 10 mM 
galactose, 2 mM glutamine, 5 mM HEPES, 1 mM sodium pyruvate, 10% FBS, and 
penicillin/streptomycin. Cells were maintained at 37 ºC, in humidified air with 5% CO2.
2.3.1. Resazurin metabolism
U2OS cells were seeded at 2.0 x 105 cells/mL in 96-well plates (200 µL/ well). After 24 
h, cells were treated with drugs (MitoPQ, paraquat, rotenone, oligomycin, myxothiazol, 
or antimycin) or solvents (DMSO or methanol). After 20 h of treatment, 40 µM rezasurin 
was added to the cells and its reduction to resorufin assessed by fluorescence readings 
8(Synergy HT, BioTek; 530 nm excitation and 590 nm emission). Readings were 
performed at 30 min intervals during 4 h (completing 24 h of treatment).
2.3.2. Huntington’s disease cell model
U2OS cells in OXPHOS-dependent conditions (galactose media) were seeded at 1.5  
105 cell/mL in 8-well glass-bottom µ-slides (80827, Ibidi), and transfected as we 
previously described (Guedes-Dias et al., 2015). For transfection with EGFP-Httex1Q23 
or EGFP-Httex1Q74 (40261 and 40262, Addgene), cells were treated with Opti-MEM, 
containing 0.5 µg plasmid DNA, 0.5 µL Lipofectamine LTX and 0.5 µL Plus reagent 
(Invitrogen) for 45 min (37 ºC, 5% CO2). 16 h after transfection, cells were treated with 
30 µM MitoPQ, 1 µM rotenone or solvent (0.3 % DMSO). Nucleus staining with Hoecsht 
34580 (1µg/mL, 30 min) and imaging was performed 24 h after treatment. EGFP-
Huntingtin (Htt) was excited at 488 nm and Hoechst at 380 nm in the NPH Imaging 
System. Transfected cells were scored as live or dead through analysis of cell (bright field 
images) and nuclear (Hoechst staining) morphologies: shrunken cells with condensed 
DNA were considered dead. Live cells were further divided as having a diffuse or 
aggregated Htt profile.
2.4. Mitochondrial membrane potential and complex analysis
 
Transfected U2OS cells were equilibrated for 30 min at 37 ºC with 50 nM TMRM+ 
(quench mode) in culture media and imaged with the NPH Imaging System. Inhibition of 
mitochondrial complexes was performed with oligomycin (6 µM; complex V), followed 
by rotenone (2 µM, complex I), and antimycin A (2 µM, complex III). Uncoupler (CCCP 
2 µM) was added at the end of the experiment. EGFP-Htt expressing cells were identified 
with 488 nm excitation, and time-lapse imaging for changes in TMRM+fluorescence was 
performed at 30s intervals with 557 nm excitation. Forward ATP synthase operation was 
detected by increased TMRM+ quenching (hyperpolarization) with oligomycin, whereas 
complex I/III inhibition or CCCP uncoupling was detected by TMRM+ dequenching 
(depolarization) (Oliveira et al., 2006; Oliveira, 2011).
92.5. Statistical analysis
Data are shown as mean  standard error of the mean (SEM) of the n number indicated 
in Figure legends, except for zebrafish survival data that are shown as Kaplan-Meier 
representations. Data from zebrafish larvae are from at least 3 different breedings. 
Concentration-response curves were fitted with non-linear regression. Global differences 
between two curves were tested with the sum-of-squares F test. For normally distributed 
data, we used the Student’s t test when comparing two groups, and the general linear 
model with Dunnet’s pos-Hoc when comparing two or more groups to a control group. 
For non-normally distributed data, we used the Kruskall-Wallis test with Dunn’s post-
Hoc for one factor analysis, and the generalized linear model for multi-factorial analyses. 
Data analyses were performed with Prism 6.0 (GraphPad) or SPSS Statistics version 25 
(IBM).
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3. Results and discussion
3.1. MitoPQ activity is mitochondria-dependent and 100-fold more potent than paraquat
MitoPQ was previously shown to induce selective mitochondrial superoxide production 
in cells (Robb et al., 2015). To extend those data, here we tested the mitochondrial-
dependency of MitoPQ toxicity in assays with U2OS cells grown in glucose media versus 
galactose media. The galactose media composition (glucose-free) limits glycolysis and 
increases the cellular dependency on mitochondria (OXPHOS-dependent conditions) 
(Dott et al., 2014). This is evidenced by data in Fig. 1, where mitochondria inhibitors with 
different targets were all found to induce a much more pronounced inhibition of resazurin 
metabolism in cells in galactose media (Fig. 1Ai-iv). In agreement with a mitochondria-
dependent activity, MitoPQ was significantly more potent in OXPHOS-dependent than 
in glycolytic conditions (Fig. 1B). In contrast, non-targeted paraquat showed no 
significant difference in potency between conditions (Fig. 1B). Moreover, MitoPQ was 
100-fold more potent than paraquat: 10 M MitoPQ induced comparable effects to 1 mM 
paraquat (Fig. 1B). This difference in potency is consistent with previous data comparing 
the hydrogen peroxide production induced by MitoPQ vs. paraquat from isolated heart 
mitochondria (Robb et al., 2015).
We next performed in vivo testing of MitoPQ in a vertebrate model. MitoPQ-
treated zebrafish presented increased hydroethidine (dihydroethidium; DHE) oxidation, 
indicating increased intracellular oxidant formation (Zielonka and Kalyanaraman, 2010) 
(Supplementary Fig. 1). Kaplan-Meier analysis of zebrafish larvae continuously exposed 
to MitoPQ or paraquat from 3 to 8 dpf revealed that both compounds induced time- and 
concentration-dependent effects on survival (Fig. 1Ci,ii). In agreement with the data from 
U2OS cells, MitoPQ was 100-fold more potent that paraquat in zebrafish (Fig. 1Ciii). 
Taken together, these results are consistent with the mitochondrial accumulation of 
MitoPQ driven by its lipophilic cation moiety (Fig. 1B; Robb et al., 2015), explaining 
both its mitochondrial-dependent effects and its higher potency than paraquat.
3.2. MitoPQ induces a parkinsonian phenotype in zebrafish
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To characterize the in vivo phenotypes induced by MitoPQ in zebrafish, we first 
monitored its effects upon sensorimotor reflexes and spontaneous swimming. Larvae 
treated for 48 h (3-5 dpf) with MitoPQ (1-10 µM) or paraquat (10-1000 µM) showed a 
concentration-dependent reduction in escape responses evoked by either tail- or head-
touch stimulation (Fig. 2A). These results indicate an impairment in evoked sensorimotor 
reflexes for both compounds, with 10 M MitoPQ again presenting similar effects to 1 
mM paraquat. Interestingly, when comparing effects on spontaneous movement, MitoPQ 
but not paraquat reduced the travelled distance and the number of initiations of movement, 
without altering movement speed (Fig. 2B). To further investigate the in vivo effects of 
MitoPQ we studied additional biochemical and functional parameters, comparing 10 M 
MitoPQ with 1 mM paraquat.
Treatment with MitoPQ (3-5 dpf) induced a significantly higher protein carbonyl 
content in zebrafish larvae than paraquat (Fig. 2C), which indicates a higher level of 
oxidative damage that contributes to the reduced spontaneous movement with MitoPQ, 
but not paraquat (Fig. 2B). To investigate if differences in energy availability might 
explain the reduced movement with MitoPQ we measured adenine nucleotide levels and 
calculated the energy charge. Treatment with either MitoPQ or paraquat from 3 to 5 dpf 
evoked no detectable changes in energy charge, although extending treatment to 6 dpf did 
significantly decrease the energy charge (Fig. 2D). This is a likely consequence of 
cumulative toxicity, together with the time-dependent depletion of yolk reserves that 
facilitates detection of drug-induced metabolic dysfunction.
We next tested if treatment with MitoPQ or paraquat affected zebrafish heart 
function, but neither treatment changed heart rate nor atrioventricular coordination, even 
when extended to 6 dpf (Fig. 2E). This lack of effect upon the zebrafish heart rate is 
compatible with previous data from the isolated mouse heart, where direct exposure to 
MitoPQ did not change the heart rate, in spite of disturbing diastolic pressures and 
coronary flow (Robb et al. 2015). Here we cannot exclude the possibility that MitoPQ 
disturbs pressure and flow of the zebrafish heart (which has a single atria and ventricle), 
but our imaging method allows detection of changes in atrioventricular coordination 
induced by mitochondrial inhibitors (Pinho et al. 2013) and such changes were not found 
in the MitoPQ-treated zebrafish. Thus, the reduced movement phenotype in MitoPQ-
treated larvae at 5dpf is unlikely to result from a widespread collapse of energy 
availability (preserved energy charge in whole-organism measurements) nor from 
generalized muscular impairment (preserved heart rate and coordination). Nevertheless, 
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there could still be major metabolic changes taking place in vulnerable tissues, which 
prompted us to investigate if MitoPQ was compromising neuronal activity.
Using tubulin acetylation levels as an indicator of neuronal structure and function, 
we found significant decreases in labelling in the midbrain region with either MitoPQ or 
paraquat treatment, (Fig. 3A), which is compatible with both compounds impairing 
sensorimotor reflexes. Using tyrosine hydroxylase (TH) levels as a marker for 
dopaminergic neuronal clusters (Sallinen et al., 2009), we found that MitoPQ, but not 
paraquat, significantly decreased brain TH levels, particularly in the pretectum and 
middle diencephalon (Fig. 3B). These two neuronal clusters express the dopamine 
transporter (Holzschuh et al., 2001) and are the most affected in zebrafish exposed to the 
dopaminergic toxin MPP+ (Sallinen et al., 2009). Thus, the differential impact of MitoPQ 
and paraquat upon these neuronal clusters could explain their differential effects upon 
spontaneous movement.
These results show that MitoPQ induces in vivo oxidative damage (increased 
protein carbonyl content) and a parkinsonian phenotype in zebrafish, particularly the 
reduced mobility and decreased brain levels of tyrosine hydroxylase that are common 
features of Parkinson’s Disease (PD) (Kordower et al., 2013). These phenotypes suggest 
that the mitochondrial superoxide production induced by MitoPQ impairs dopaminergic 
neurotransmission. This is in agreement with dopaminergic neurons being highly 
vulnerable to oxidative stress (Wang and Michaelis, 2010; Yu et al., 2016), and with PD 
patients presenting oxidative stress markers and monoaminergic dysregulation (Engeln et 
al., 2015; Michell et al., 2004; Ng et al., 2015).
3.3. Rescue of MitoPQ-induced phenotypes with antioxidant or monoaminergic 
potentiation strategies
Given the pro-oxidant properties of MitoPQ and the sensorimotor phenotypes associated 
with reduced TH (a key enzyme in the synthesis of dopamine and other monoamine 
neurotransmitters), we tested if these phenotypes could be rescued with antioxidant or 
monoaminergic potentiation strategies. For this purpose, we used the antioxidant N-
acetyl-L-cystein (NAC; (Samuni et al., 2013)) and desipramine – an inhibitor of the 
reuptake of monoamine neurotransmitters (Deng et al., 2016). We selected the 
concentrations of 1 mM NAC and 10 µM desipramine based on previous determination 
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of efficacy (Lin et al., 2012; Pan et al., 2018; Sackerman et al., 2010; Samuni et al., 2013), 
and lack of effect on zebrafish survival under our experimental conditions 
(Supplementary Fig. 2).
NAC or desipramine alone, from 3 to 5 dpf, had no effect on zebrafish 
sensorimotor reflexes, but in co-treatment with MitoPQ they significantly rescued the 
impairment of head or tail touch responses by MitoPQ (Fig. 4A). NAC alone evoked no 
changes in spontaneous movement, whereas desipramine alone significantly decreased 
the swimming distance (Fig. 4B). We therefore focused on co-treatment with NAC and 
found that it significantly attenuated the spontaneous movement impairment evoked by 
MitoPQ (Fig. 4B). We next tested if this movement recovery correlated with 
neurochemical changes. Although NAC co-treatment failed to significantly recover 
alpha-tubulin acetylation in the midbrain (Fig. 4C), it significantly increased TH levels in 
the pretectum (Fig. 4D) – the region showing the largest decrease evoked by MitoPQ 
(Fig. 3B). Mechanistically, the superoxide generated by MitoPQ is rapidly converted to 
hydrogen peroxide, which crosses mitochondrial membranes and generates other reactive 
species that induce widespread oxidative damage (Murphy, 2009; Sena and Chandel, 
2012; Willems et al., 2015). NAC may quench this widespread damage by being a source 
of sulfhydryl groups that scavenge free radicals and protect protein disulfide bonds 
(Elbini Dhouib et al., 2016; Samuni et al., 2013).
These results show that the Parkinson’s like phenotypes induced by MitoPQ in 
zebrafish can be partially ameliorated by the indicated pharmacological strategies 
(antioxidant and monoaminergic potentiation), highlighting the potential of MitoPQ as a 
tool for in vivo redox biology research. We next decided to test MitoPQ in another 
experimental model of disease.
3.4. MitoPQ increases huntingtin aggregation in a cell model of Huntington’s disease
Given that treatment with MitoPQ generated a parkinsonian phenotype in zebrafish, 
which may also be interpreted as accelerated ageing (Collier et al., 2011), we decided to 
test how treatment with MitoPQ affects survival of a cell model of Huntington’s disease 
(HD) and the proteostasis of the disease associated protein – huntingtin (Htt). As with 
PD, HD pathophysiology includes mitochondrial dysfunction (Guedes-Dias et al., 2016) 
and age-dependent neurodegeneration (Lee and Kim, 2006). HD progresses with 
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increased formation of mutant Htt aggregates that evoke a slow, necrotic death (Ramdzan 
et al., 2017).
To model HD, we used U2OS cells expressing GFP-tagged wild-type (Q23) or 
mutant (Q74) Htt constructs, in OXPHOS-dependent conditions (galactose media), and 
treated with MitoPQ for 24 h. Solvent alone and rotenone were used for comparison with 
the effects of MitoPQ. Concentrations of 30 µM MitoPQ and 1 µM rotenone produced 
similar effects on metabolism in OXPHOS-dependent conditions (Fig. 1 A vs. C). Under 
control conditions, cells expressing Q23-Htt showed a diffuse GFP distribution with no 
detectable aggregates (Fig. 5A). In contrast, cells expressing Q74-Htt showed aggregates 
and a significantly higher cell death than Q23-Htt cells (Fig. 5B). Treatment with MitoPQ 
increased Q74-Htt aggregation without increasing cell death in cells expressing Q23- or 
Q74-Htt. This differs from treatment with rotenone where we observed a significant 
increase in cell death, particularly in cells expressing Q23-Htt. 
How might MitoPQ promote mHtt aggregation? While H2O2 diffusion from 
MitoPQ-challenged mitochondria might modify mHtt directly, promoting its aggregation 
(Kumar and Ratan, 2017), particularly near mitochondria (Fig. 6A), there is currently 
more evidence for indirect effects of ROS via impairments in the proteostasis machinery 
(Fig. 6C). Oxidative stress was found to promote mHtt aggregation in association with 
proteasomal dysfunction (Goswami et al., 2006) and, particularly, mitochondria-derived 
ROS was found to reduce the activity of the ubiquitin-proteasome system (Segref et al., 
2014; D’Amico et al., 2017). Additionally, mitochondria-derived ROS might promote 
mHtt aggregation by compromising the activity of molecular chaperones, which are 
vulnerable to ROS-mediated oxidation (Sorolla et al., 2012).
These results indicate that the use of MitoPQ as a co-stressor, to accelerate disease 
phenotypes, has advantages over classical mitochondrial inhibitors such as rotenone, 
namely by avoiding cell death under control conditions. Further, these results suggest that 
MitoPQ is an interesting tool to study the effects of increased mitochondrial superoxide 
production on huntingtin proteostasis, and possibly that of other mutant proteins in 
disease models. 
It is important to note that neurodegenerative disorders are associated with 
decreased mitochondrial membrane potential (Chaturvedi and Beal, 2013). Since MitoPQ 
uptake into mitochondria depends on mitochondrial membrane potential, it may be more 
useful in models of early stage disease where mitochondrial membrane potential is still 
maintained at normal levels. In our experimental conditions, at the time of treating with 
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MitoPQ, cells expressing either diffuse or aggregated mHtt retained mitochondrial 
membrane potential (TMRM+ staining) and were net ATP generators (oligomycin 
hyperpolarization) (Fig. 6B). As with other drugs or probes influenced by mitochondrial 
membrane potential (Polster et al., 2015), the mitochondrial polarization status should 
thus be taken into consideration when using MitoPQ.
4. Conclusions
The generation of mitochondrial superoxide plays an important role in ROS signalling 
and oxidative damage, but the lack of strategies for its selective generation have limited 
advancement in this field of research. The mitochondrial superoxide generator MitoPQ 
was recently developed as a tool to overcome this limitation, and here we present its first 
in vivo study in a vertebrate model. MitoPQ induces a parkinsonian phenotype in 
zebrafish larvae, supporting a contribution of mitochondrial superoxide generation to the 
development of PD. MitoPQ also led to an increase in mutant huntingtin aggregation in 
a cell model. These data suggest that MitoPQ can accelerate ageing-associated processes 
in vivo and in cell models.  MitoPQ is thus an interesting co-stressor to accelerate disease 
phenotypes, and a valuable tool to investigate the role of mitochondrial superoxide 
generation in physiological and pathological processes, using cellular and in vivo models.
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Figure Legends
Figure 1. Drug effects on cell metabolism and zebrafish survival.  (A) Resazurin 
metabolism of U2OS cells grown in glucose media (glycolytic conditions) and galactose 
media (OXPHOS-dependent conditions), after 24 h of treatment with increasing 
concentration of mitochondrial inhibitors: (i) rotenone – complex I inhibitor, (ii and iii) 
myxothiazol and antimycin – complex III inhibitors; and (iv) oligomycin – ATP synthase 
inhibitor; n = 3-4 independent experiments. (B) Resazurin metabolism of U2OS cells in 
glucose versus galactose media after treatment with MitoPQ and paraquat (left); and their 
chemical structures (right). Note that the decyl triphenylphosphonium lipophilic cation 
moiety targets MitoPQ to polarized mitochondria, and that MitoPQ was 100-fold more 
potent than paraquat in galactose media; n=3 independent experiments, *P< 0.05. (C) 
Kaplan-Meier survival analysis of zebrafish larvae exposed to MitoPQ (i), paraquat (ii), 
or solvent (control), n=24-50 larvae; and respective median survival times (iii).  
Figure 2. Behavioral, functional and biochemical parameters in zebrafish treated 
with MitoPQ vs. Paraquat. Zebrafish were treated with the indicated concentrations of 
MitoPQ and paraquat, or solvent (control), from 3 dpf until measurements (at 5 or 6 dpf). 
(A, B) Sensorimotor reflexes and spontaneous movement at 5 dpf: (Ai) tail and (Aii) head 
reflexes; (Bi) representative trajectories; (Bii) distance; (Biii) initiations, and (Biv) 
movement speed; n=27-78 larvae; *P<0.05 vs. control. (C) Protein carbonyl groups 
measured by dot-blot at 5 dpf. n=3 independent experiments, *P< 0.05 vs. control. (D) 
Left – energy charge values, calculated with the indicated formula, at 5 dpf (triangles) 
and 6 dpf (circles); Right – representative HPLC chromatogram with adenine nucleotides; 
n=3-4 independent experiments. (E) Heart rate and atrioventricular coordination at 6 dpf; 
n=16-19 larvae.
Figure 3. Brain levels of acetylated--tubulin and tyrosine hydroxylase (TH) in 
zebrafish treated with MitoPQ vs. paraquat. Larvae were treated from 3 to 5 dpf with 
10 µM MitoPQ, 1 mM paraquat, or solvent (control). Acetylated--tubulin and TH were 
quantified by immunofluorescence at 5 dpf. (A) Representative images and quantification 
of acetylated--tubulin in the midbrain; n=7-11 larvae, *P< 0.05 vs. control. (B) 
Representative images of TH-positive neurons and quantification of TH levels in (i) the 
22
pretectum, (ii) middle diencephalon and (iii) hypothalamus. The first column shows 
global TH staining in blue, with a yellow highlight for the region under analysis; n=16-
18 larvae, *P < 0.05 vs. control.  
Figure 4. Effects of N-acetyl-L-cystein and desipramine on the behavioral and 
neurochemical phenotypes of MitoPQ-treated larvae. Larvae were treated from 3 to 5 
dpf with solvent (control), 10 µM MitoPQ, 1 mM N-acetyl-L-cystein (NAC), or 10 µM 
desipramine, alone or in the indicated combinations. (A) Sensorimotor reflexes at 5 dpf; 
(B) Spontaneous swimming distances at 5 dpf; n=19-54 larvae. (C) Representative 
acetylated--tubulin immunofluorescence in the midbrain and its quantification; n=7-11 
larvae. (D) Representative tyrosine hydroxylase immunofluorescence showing neuronal 
clusters in the pretectum and associated quantifications; n=13-18 larvae. *P< 0.05 vs. 
control; #P< 0.05 vs. MitoPQ 
Figure 5. Effects of MitoPQ on huntingtin proteostasis and cell viability in a HD cell 
model. U2OS cells transfected with GFP-Httex1Q23 or GFP-Httex1Q74 were treated for 
24 h with 30 µM MitoPQ, 1 µM rotenone, or solvent (control). (A) Huntingtin expression 
(EGFP) and nucleus staining (Hoechst 34580). Representative images show cells with 
Htt in diffuse form (Q23 and Q74) and Htt aggregates (observed only with Q74). (B) 
Quantification of live cells presenting (i) only diffuse huntingtin or (ii) containing 
aggregates; and (iii) cell death. n=6 independent experiments, *P< 0.05 vs. Q23; #P< 0.05 
vs. Q74.  
Figure 6. Mitochondria and ROS-mediated impairment of huntingtin proteostasis. 
(A) Representative U2OS cells expressing diffuse (left) and aggregated (right) mHtt-
EGFP (green) in proximity of TMRM+-stained mitochondria (red). (B) Representative 
tracings of changes in TMRM+ fluorescence of U2OS cells exposed to the indicated 
drugs: O, 6 µM oligomycin; R, 2 µM rotenone; A, 2 µM antimycin A; C, 2 µM CCCP; 
(i) non-transfected cell; (ii) cell expressing mHtt-EGFP, 24h-post transfection; tracings 
are representative of at least 10 cells per condition. (C) Mitoparaquat promotes 
mitochondria superoxide formation (Robb et al., 2015), arguably accelerating a process 
that is also thought to occur in the presence of mutant huntingtin (mHtt; Puranam et al., 
2006; Wang et al., 2013). Mitochondria-derived reactive-oxygen species (ROS) impair 
the ubiquitin-proteasome system (Goswami et al., 2006; Segref et al., 2014; D’Amico et 
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al., 2017), and may also impair chaperones (Sorolla et al., 2012; Kumar and Ratan 2017), 
limiting mHtt degradation and thereby promoting its accumulation and aggregation. 
Increased levels of mHtt promote its interaction with mitochondria, and ROS formation 
(Puranam et al., 2006; Wang et al., 2013). Such ROS, together with those generated from 
mHtt aggregation (Hands et al., 2011) may modify mHtt directly, further promoting its 
aggregation (Kumar and Ratan 2017).
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2Abstract
Superoxide generation by mitochondria respiratory complexes is a major source of 
reactive oxygen species (ROS) which are capable of initiating redox signalling and 
oxidative damage. Current understanding of the role of mitochondrial ROS in health and 
disease has been limited by the lack of experimental strategies to selectively induce 
mitochondrial superoxide production. The recently-developed mitochondria-targeted 
redox cycler MitoParaquat (MitoPQ) overcomes this limitation, and has proven effective 
in vitro and in Drosophila. Here we present an in vivo study of MitoPQ in the vertebrate 
zebrafish model in the context of Parkinson’s disease (PD), and in a human cell model of 
Huntington’s disease (HD). We show that MitoPQ is 100-fold more potent than non-
targeted paraquat in both cells and in zebrafish in vivo. Treatment with MitoPQ induced 
a parkinsonian phenotype in zebrafish larvae, with decreased sensorimotor reflexes, 
spontaneous movement and brain tyrosine hydroxylase (TH) levels, without detectable 
effects on heart rate or atrioventricular coordination. Motor phenotypes and TH levels 
were partly rescued with antioxidant or monoaminergic potentiation strategies. In a HD 
cell model, MitoPQ promoted mutant huntingtin aggregation without increasing cell 
death, contrasting with the complex I inhibitor rotenone that increased death in cells 
expressing either wild-type or mutant huntingtin. These results show that MitoPQ is a 
valuable tool for cellular and in vivo studies of the role of mitochondrial superoxide 
generation in redox biology, and as a trigger or co-stressor to model metabolic and 
neurodegenerative disease phenotypes. 
Keyworks: Mitochondria, MitoParaquat, Zebrafish, Parkinson’s disease, Huntington’s 
disease, Superoxide
Abbreviations: Dpf, days post fertilization; HD, Huntington’s disease; Htt, Huntingtin; 
mHtt, mutant huntingtin; MitoPQ, MitoParaquat; NAC, N-acetyl-L-cysteine; OXPHOS, 
oxidative phosphorylation; PBST, phosphate buffer solution with 0.05% Tween 20; PD, 
Parkinson’s disease; ROS, reactive oxygen species; TH, tyrosine hydroxylase; 
31. Introduction 
Reactive oxygen species (ROS) were originally characterized as cell-damaging by-
products of biological reactions. There is now compelling evidence that ROS also 
participate in physiological signaling, regulating redox-dependent switches in proteins 
that govern proliferation, metabolism, gene transcription, inflammation and ageing 
(Drazic and Winter, 2014; Holmstrom and Finkel, 2014; Sena and Chandel, 2012). 
Superoxide produced by mitochondrial respiratory complexes is a major source of ROS, 
involved in signaling to other cellular compartments and in oxidative damage (Angelova 
and Abramov, 2016). Available strategies to increase mitochondrial superoxide include 
respiratory complex inhibitors, which disturb the membrane potential and ATP synthesis 
(Murphy, 2009), and non-targeted redox cyclers, which lead to substantial superoxide 
production outside mitochondria (Cocheme and Murphy, 2008), thereby confounding 
data interpretation. Thus, the current understanding of the pathophysiological role of 
mitochondrial superoxide has been limited by the lack of strategies to selectively increase 
its generation in cells and in vivo (Holmstrom and Finkel, 2014).
MitoParaquat (MitoPQ) is a recently developed molecule comprising the redox cycler 
paraquat conjugated to a mitochondria-targeting triphenylphosphonium lipophilic cation. 
MitoPQ accumulates in energized mitochondria and produces superoxide by redox 
cycling at complex I. It was previously shown in vitro that MitoPQ increases 
mitochondrial superoxide production in cells, and disturbs cardiac function in the isolated 
perfused mouse heart (Robb et al., 2015). There is currently limited information on the in 
vivo effects of MitoPQ, particularly in disease models. In vivo, MitoPQ was previously 
tested only in flies (Drosophila melanogaster), where it was found to reduce lifespan, 
without further functional or behavioral analyses (Robb et al., 2015). Here we have 
performed the first in vivo characterization of the effects of MitoPQ in a vertebrate model, 
the zebrafish (Danio rerio). We also assessed the usefulness of MitoPQ in the context of 
neurodegenerative disease modeling in cells. 
Zebrafish is well-suited for in vivo drug screening given its advantages, including 
larval transparency (allowing non-invasive studies of cardiac function), reduced size 
(facilitating behavioral evaluation), and high genetic and physiological homology to 
mammals (Stewart et al., 2014). The zebrafish is increasingly used to study 
neurodegenerative disorders (Pinho et al., 2016; Veldman et al., 2015) and associated 
processes such as mitochondrial dysfunction (Artuso et al., 2012; Pinho et al., 2013) and 
4oxidative stress (Fang and Miller, 2012; Gauron et al., 2013; Massarsky et al., 2017; 
Muller et al., 2018). 
Here we investigate in vivo mitochondrial superoxide generation by MitoPQ in 
zebrafish.  Complementing prior evidence that MitoPQ selectively generates superoxide 
within mitochondria (Robb et al., 2015), we show here the higher potency of MitoPQ vs. 
paraquat in cells and in zebrafish. We further show that MitoPQ induces a parkinsonian 
phenotype in zebrafish, with decreased spontaneous movement and brain tyrosine 
hydroxylase levels. We also tested MitoPQ in a Huntington’s disease cellular model 
where it increased mutant huntingtin (mHtt) aggregation. These results support MitoPQ 
as a useful tool for investigating superoxide production in pathology in animal and cell 
models of disease.   
2. Material and Methods
2.1. Drugs, solvents and solutions
MitoPQ was synthesised as previously described (Robb et al., 2015). Culture media and 
supplements were from Gibco. Paraquat, N-acetyl-L-cysteine (NAC), desipramine, 
rotenone, myxothiazol, antimycin A, oligomycin B, and all other drugs or reagents were 
from Sigma-Aldrich, unless otherwise stated. MitoPQ, rotenone and oligomycin stock 
solutions were prepared in dimethyl sulfoxide (DMSO), whereas those from desipramine, 
paraquat, and NAC were prepared in water. Myxothiazol and antimycin stock solutions 
were prepared in methanol. Experiments in zebrafish larvae were performed with 0.1 – 
0.5% DMSO. Experiments in U2OS cells were performed in presence of 0.1 - 0.5% 
DMSO or 0.1% methanol.  Control treatment conditions contained the same amount of 
solvent (DMSO or methanol) as the respective drug treatment conditions.
2.2. Zebrafish maintenance and drug treatments 
Adult wild-type zebrafish (Danio rerio) or larvae were maintained at 28 ± 1ºC with 
14h:10h light:dark cycles and handled for egg production as we previously described 
(Pinho et al., 2016; Pinho et al., 2013). Fertilized eggs were kept in autoclaved water 
containing 1 µM methylene blue until 3 days post fertilization (dpf). At 3 dpf, hatched 
5larvae without detectable abnormalities were randomly distributed into multi-well plates, 
containing autoclaved water and exposed to treatments (MitoPQ, paraquat, NAC, 
desipramine, or solvent). In all experiments, larvae were imaged daily with a 
stereomicroscope to assess viability. Dead larvae were removed, and half volume was 
replaced with freshly prepared treatment solutions (Pinho et al., 2016). For survival and 
movement experiments, larvae were exposed to drugs in 24-well plates (5 larvae/ 500 µL/ 
well), while to assess cardiovascular function, larvae were exposed to drugs in 96-well 
plates (1 larvae/ 200 µL/ well). In population assays, such as quantification of adenosine 
nucleotides and dot-blot, as well as for immunofluorescence, larvae were exposed to 
drugs in 12-well plates (15-30 larvae/ 1mL/ well). 
2.2.1. Cardiovascular function
At 5 and 6 dpf, larvae were anaesthetized with 0.8 M tricaine methanesulfonate and their 
heartbeats recorded for 30s, at 10x magnification in a customised Nikon-Prior-
Hamamatsu (NPH) Imaging System, composed by an inverted microscope (Eclipse 
TE300, Nikon), a motorized stage (ProScan, Prior), a CCD camera (ORCA-ER, 
Hamamatsu), and a monochromator (Polychrome II, Photonics), all controlled by the 
open source software Micro-Manager (v. 2.0; https://micro-manager.org). Videos were 
captured at 30 frames per second (fps) and processed with ImageJ 
(https://imagej.nih.gov/ij/) for assessing atrioventricular coordination and heart rate. 
2.2.2. Adenine nucleotides and energy charge 
Nucleotide extraction was performed at 5 and 6 dpf, as we previously described (Pinho 
et al., 2016), but now using a Precellys 24 homogenizer (Bertin Technologies) at 6800 
rpm (3 x 20s, CK28 beads). ATP, ADP and AMP were quantified using HPLC (reversed-
phase column; 2504.6mm Luna 5µm C18(2) 100Å; Phenomenex) with a diode-array 
detector (Agilent 1100 series), measuring 260 nm absorbance. Energy charge was 
calculated with the formula: ([ATP]+0.5[ADP])  ([ATP]+[ADP]+[AMP]) (Torrecilla et 
al., 2001).
2.2.3. Behavioural evaluation
6Measurements of spontaneous swimming and sensorimotor reflexes were performed at 5 
dpf, as we previously described (Pinho et al., 2016). Briefly, individual larvae in 6-well 
plates were recorded for 10 min at 28  1 ºC with a HD digital camera (C525, Logitech). 
Videos were processed with iWisoft (www.iwisoft.com/videoconverter) and ImageJ to 
extract time and spatial coordinates. Calculations were automated in customised 
spreadsheets (Excel, Microsoft) to derive movement parameters: distance (cm), 
movement speed (distance  time in movement; mm/s), and initiations. After the 
spontaneous swimming, each larva was tested for reflexes by gently touching with a 
micropipette tip in the head and in the tail. Immediate swimming after touch was scored 
as a positive response. Head and tail touches were alternated, spaced by 30 s, and the 
procedure repeated 10 times for each larva. 
2.2.4. Quantification of protein carbonyl groups
Protein extraction was performed at 5 dpf by sonication of 45 larvae in ice-cold lysis 
buffer (250 mM sucrose; 20 mM HEPES; 3 mM EDTA, pH=7.5) supplemented with a 
protease inhibitor cocktail (Fisher Scientific). After 3 freeze-thaw cycles, lysates were 
centrifuged at 300g (10 min, 4 ºC) and carbonyls quantified in the supernatant. Protein 
was quantified according to Bradford method and carbonyl derivatization was performed 
as previously described (Levine et al., 1994), with minor modifications. Briefly, 200 µL 
of protein extract containing 20 µg protein were incubated with 200 µL of 12% sodium 
dodecyl sulfate and 400 µL of 20 mM 2,4-dinitrophenylhydrazine hydrochloride (TCI 
Europe) for 30 min in the dark. After neutralization with 300 µL of 2 M Tris with 18% 
-mercaptoethanol, samples containing 1µg of protein were spotted on a nitrocellulose 
membrane (Bio-Dot Microfiltration Apparatus, Bio-Rad). Membranes were blocked for 
1 h with 5% bovine serum albumin in PBST (phosphate buffer solution with 0.05% 
Tween 20), and incubated with anti-dinitrophenol antibody (MAB2223, 1:1000, Sigma-
Aldrich; 1 h). After washing with PBST, membranes were incubated with secondary 
antibody (G-21040, 1:4000; Life Technologies; 1 h), and imaged using a 
Chemiluminescent kit (Novex ECL, Life Technologies) and a ChemiDoc MP (Bio-Rad). 
Coomassie staining was used for loading control. Densitometric analyses were performed 
with Image J.
72.2.6. Immunofluorescence 
At 5 dpf, larvae were fixed (4% paraformaldehyde, overnight at 4ºC) and processed for 
immunofluorescence as we previously described (Pinho et al., 2016). Primary antibodies: 
anti-acetylated--tubulin (T6793, Sigma-Aldrich; 1:1000) or anti-tyrosine hydroxylase 
(TH) (MAB318, Merck Millipore; 1:500) overnight at 4 ºC. Secondary antibody: anti-
mouse AlexaFluor-488 (A-11029, Life Technologies) overnight at 4 ºC. Larvae mounted 
in Glycergel medium (DAKO) were imaged in the aforementioned NPH Imaging System. 
For intensity comparisons, non-saturated images were acquired with identical equipment 
settings. The mean intensity of immunofluorescence was quantified after background 
subtraction using ImageJ. 
2.3. U2OS cell maintenance
Human U2OS cells have been previously used to study mHtt aggregation (Bersuker et 
al., 2013). These cells are advantageous for their high transfection efficiencies, and also 
for imaging studies (large, flat cells with clearly-defined nuclear and cytosolic 
compartments), explaining their widespread use, including in neurodegenerative disease 
contexts (Becker et al., 2017; Bersuker et al., 2013; Rasool et al., 2018). Here, U2OS cells 
(ATCC) were cultured in either glucose media (glycolytic conditions) or galactose media 
(oxidative phosphorylation – OXPHOS – dependent conditions). Glucose media was 
composed by Dulbecco’s Modified Eagle’s Medium (DMEM) with low glucose 
supplemented with 10% foetal bovine serum (FBS) and penicillin/streptomycin. 
Galactose media was composed by DMEM without glucose supplemented with 10 mM 
galactose, 2 mM glutamine, 5 mM HEPES, 1 mM sodium pyruvate, 10% FBS, and 
penicillin/streptomycin. Cells were maintained at 37 ºC, in humidified air with 5% CO2.
2.3.1. Resazurin metabolism
U2OS cells were seeded at 2.0 x 105 cells/mL in 96-well plates (200 µL/ well). After 24 
h, cells were treated with drugs (MitoPQ, paraquat, rotenone, oligomycin, myxothiazol, 
or antimycin) or solvents (DMSO or methanol). After 20 h of treatment, 40 µM rezasurin 
was added to the cells and its reduction to resorufin assessed by fluorescence readings 
8(Synergy HT, BioTek; 530 nm excitation and 590 nm emission). Readings were 
performed at 30 min intervals during 4 h (completing 24 h of treatment).
2.3.2. Huntington’s disease cell model
U2OS cells in OXPHOS-dependent conditions (galactose media) were seeded at 1.5  
105 cell/mL in 8-well glass-bottom µ-slides (80827, Ibidi), and transfected as we 
previously described (Guedes-Dias et al., 2015). For transfection with EGFP-Httex1Q23 
or EGFP-Httex1Q74 (40261 and 40262, Addgene), cells were treated with Opti-MEM, 
containing 0.5 µg plasmid DNA, 0.5 µL Lipofectamine LTX and 0.5 µL Plus reagent 
(Invitrogen) for 45 min (37 ºC, 5% CO2). 16 h after transfection, cells were treated with 
30 µM MitoPQ, 1 µM rotenone or solvent (0.3 % DMSO). Nucleus staining with Hoecsht 
34580 (1µg/mL, 30 min) and imaging was performed 24 h after treatment. EGFP-
Huntingtin (Htt) was excited at 488 nm and Hoechst at 380 nm in the NPH Imaging 
System. Transfected cells were scored as live or dead through analysis of cell (bright field 
images) and nuclear (Hoechst staining) morphologies: shrunken cells with condensed 
DNA were considered dead. Live cells were further divided as having a diffuse or 
aggregated Htt profile.
2.4. Mitochondrial membrane potential and complex analysis
 
Transfected U2OS cells were equilibrated for 30 min at 37 ºC with 50 nM TMRM+ 
(quench mode) in culture media and imaged with the NPH Imaging System. Inhibition of 
mitochondrial complexes was performed with oligomycin (6 µM; complex V), followed 
by rotenone (2 µM, complex I), and antimycin A (2 µM, complex III). Uncoupler (CCCP 
2 µM) was added at the end of the experiment. EGFP-Htt expressing cells were identified 
with 488 nm excitation, and time-lapse imaging for changes in TMRM+fluorescence was 
performed at 30s intervals with 557 nm excitation. Forward ATP synthase operation was 
detected by increased TMRM+ quenching (hyperpolarization) with oligomycin, whereas 
complex I/III inhibition or CCCP uncoupling was detected by TMRM+ dequenching 
(depolarization) (Oliveira et al., 2006; Oliveira, 2011).
92.5. Statistical analysis
Data are shown as mean  standard error of the mean (SEM) of the n number indicated 
in Figure legends, except for zebrafish survival data that are shown as Kaplan-Meier 
representations. Data from zebrafish larvae are from at least 3 different breedings. 
Concentration-response curves were fitted with non-linear regression. Global differences 
between two curves were tested with the sum-of-squares F test. For normally distributed 
data, we used the Student’s t test when comparing two groups, and the general linear 
model with Dunnet’s pos-Hoc when comparing two or more groups to a control group. 
For non-normally distributed data, we used the Kruskall-Wallis test with Dunn’s post-
Hoc for one factor analysis, and the generalized linear model for multi-factorial analyses. 
Data analyses were performed with Prism 6.0 (GraphPad) or SPSS Statistics version 25 
(IBM).
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3. Results and discussion
3.1. MitoPQ activity is mitochondria-dependent and 100-fold more potent than paraquat
MitoPQ was previously shown to induce selective mitochondrial superoxide production 
in cells (Robb et al., 2015). To extend those data, here we tested the mitochondrial-
dependency of MitoPQ toxicity in assays with U2OS cells grown in glucose media versus 
galactose media. The galactose media composition (glucose-free) limits glycolysis and 
increases the cellular dependency on mitochondria (OXPHOS-dependent conditions) 
(Dott et al., 2014). This is evidenced by data in Fig. 1, where mitochondria inhibitors with 
different targets were all found to induce a much more pronounced inhibition of resazurin 
metabolism in cells in galactose media (Fig. 1Ai-iv). In agreement with a mitochondria-
dependent activity, MitoPQ was significantly more potent in OXPHOS-dependent than 
in glycolytic conditions (Fig. 1B). In contrast, non-targeted paraquat showed no 
significant difference in potency between conditions (Fig. 1B). Moreover, MitoPQ was 
100-fold more potent than paraquat: 10 M MitoPQ induced comparable effects to 1 mM 
paraquat (Fig. 1B). This difference in potency is consistent with previous data comparing 
the hydrogen peroxide production induced by MitoPQ vs. paraquat from isolated heart 
mitochondria (Robb et al., 2015).
We next performed in vivo testing of MitoPQ in a vertebrate model. MitoPQ-
treated zebrafish presented increased hydroethidine (dihydroethidium; DHE) oxidation, 
indicating increased intracellular oxidant formation (Zielonka and Kalyanaraman, 2010) 
(Supplementary Fig. 1). Kaplan-Meier analysis of zebrafish larvae continuously exposed 
to MitoPQ or paraquat from 3 to 8 dpf revealed that both compounds induced time- and 
concentration-dependent effects on survival (Fig. 1Ci,ii). In agreement with the data from 
U2OS cells, MitoPQ was 100-fold more potent that paraquat in zebrafish (Fig. 1Ciii). 
Taken together, these results are consistent with the mitochondrial accumulation of 
MitoPQ driven by its lipophilic cation moiety (Fig. 1B; Robb et al., 2015), explaining 
both its mitochondrial-dependent effects and its higher potency than paraquat.
3.2. MitoPQ induces a parkinsonian phenotype in zebrafish
11
To characterize the in vivo phenotypes induced by MitoPQ in zebrafish, we first 
monitored its effects upon sensorimotor reflexes and spontaneous swimming. Larvae 
treated for 48 h (3-5 dpf) with MitoPQ (1-10 µM) or paraquat (10-1000 µM) showed a 
concentration-dependent reduction in escape responses evoked by either tail- or head-
touch stimulation (Fig. 2A). These results indicate an impairment in evoked sensorimotor 
reflexes for both compounds, with 10 M MitoPQ again presenting similar effects to 1 
mM paraquat. Interestingly, when comparing effects on spontaneous movement, MitoPQ 
but not paraquat reduced the travelled distance and the number of initiations of movement, 
without altering movement speed (Fig. 2B). To further investigate the in vivo effects of 
MitoPQ we studied additional biochemical and functional parameters, comparing 10 M 
MitoPQ with 1 mM paraquat.
Treatment with MitoPQ (3-5 dpf) induced a significantly higher protein carbonyl 
content in zebrafish larvae than paraquat (Fig. 2C), which indicates a higher level of 
oxidative damage that contributes to the reduced spontaneous movement with MitoPQ, 
but not paraquat (Fig. 2B). To investigate if differences in energy availability might 
explain the reduced movement with MitoPQ we measured adenine nucleotide levels and 
calculated the energy charge. Treatment with either MitoPQ or paraquat from 3 to 5 dpf 
evoked no detectable changes in energy charge, although extending treatment to 6 dpf did 
significantly decrease the energy charge (Fig. 2D). This is a likely consequence of 
cumulative toxicity, together with the time-dependent depletion of yolk reserves that 
facilitates detection of drug-induced metabolic dysfunction.
We next tested if treatment with MitoPQ or paraquat affected zebrafish heart 
function, but neither treatment changed heart rate nor atrioventricular coordination, even 
when extended to 6 dpf (Fig. 2E). This lack of effect upon the zebrafish heart rate is 
compatible with previous data from the isolated mouse heart, where direct exposure to 
MitoPQ did not change the heart rate, in spite of disturbing diastolic pressures and 
coronary flow (Robb et al. 2015). Here we cannot exclude the possibility that MitoPQ 
disturbs pressure and flow of the zebrafish heart (which has a single atria and ventricle), 
but our imaging method allows detection of changes in atrioventricular coordination 
induced by mitochondrial inhibitors (Pinho et al. 2013) and such changes were not found 
in the MitoPQ-treated zebrafish. Thus, the reduced movement phenotype in MitoPQ-
treated larvae at 5dpf is unlikely to result from a widespread collapse of energy 
availability (preserved energy charge in whole-organism measurements) nor from 
generalized muscular impairment (preserved heart rate and coordination). Nevertheless, 
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there could still be major metabolic changes taking place in vulnerable tissues, which 
prompted us to investigate if MitoPQ was compromising neuronal activity.
Using tubulin acetylation levels as an indicator of neuronal structure and function, 
we found significant decreases in labelling in the midbrain region with either MitoPQ or 
paraquat treatment, (Fig. 3A), which is compatible with both compounds impairing 
sensorimotor reflexes. Using tyrosine hydroxylase (TH) levels as a marker for 
dopaminergic neuronal clusters (Sallinen et al., 2009), we found that MitoPQ, but not 
paraquat, significantly decreased brain TH levels, particularly in the pretectum and 
middle diencephalon (Fig. 3B). These two neuronal clusters express the dopamine 
transporter (Holzschuh et al., 2001) and are the most affected in zebrafish exposed to the 
dopaminergic toxin MPP+ (Sallinen et al., 2009). Thus, the differential impact of MitoPQ 
and paraquat upon these neuronal clusters could explain their differential effects upon 
spontaneous movement.
These results show that MitoPQ induces in vivo oxidative damage (increased 
protein carbonyl content) and a parkinsonian phenotype in zebrafish, particularly the 
reduced mobility and decreased brain levels of tyrosine hydroxylase that are common 
features of Parkinson’s Disease (PD) (Kordower et al., 2013). These phenotypes suggest 
that the mitochondrial superoxide production induced by MitoPQ impairs dopaminergic 
neurotransmission. This is in agreement with dopaminergic neurons being highly 
vulnerable to oxidative stress (Wang and Michaelis, 2010; Yu et al., 2016), and with PD 
patients presenting oxidative stress markers and monoaminergic dysregulation (Engeln et 
al., 2015; Michell et al., 2004; Ng et al., 2015).
3.3. Rescue of MitoPQ-induced phenotypes with antioxidant or monoaminergic 
potentiation strategies
Given the pro-oxidant properties of MitoPQ and the sensorimotor phenotypes associated 
with reduced TH (a key enzyme in the synthesis of dopamine and other monoamine 
neurotransmitters), we tested if these phenotypes could be rescued with antioxidant or 
monoaminergic potentiation strategies. For this purpose, we used the antioxidant N-
acetyl-L-cystein (NAC; (Samuni et al., 2013)) and desipramine – an inhibitor of the 
reuptake of monoamine neurotransmitters (Deng et al., 2016). We selected the 
concentrations of 1 mM NAC and 10 µM desipramine based on previous determination 
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of efficacy (Lin et al., 2012; Pan et al., 2018; Sackerman et al., 2010; Samuni et al., 2013), 
and lack of effect on zebrafish survival under our experimental conditions 
(Supplementary Fig. 2).
NAC or desipramine alone, from 3 to 5 dpf, had no effect on zebrafish 
sensorimotor reflexes, but in co-treatment with MitoPQ they significantly rescued the 
impairment of head or tail touch responses by MitoPQ (Fig. 4A). NAC alone evoked no 
changes in spontaneous movement, whereas desipramine alone significantly decreased 
the swimming distance (Fig. 4B). We therefore focused on co-treatment with NAC and 
found that it significantly attenuated the spontaneous movement impairment evoked by 
MitoPQ (Fig. 4B). We next tested if this movement recovery correlated with 
neurochemical changes. Although NAC co-treatment failed to significantly recover 
alpha-tubulin acetylation in the midbrain (Fig. 4C), it significantly increased TH levels in 
the pretectum (Fig. 4D) – the region showing the largest decrease evoked by MitoPQ 
(Fig. 3B). Mechanistically, the superoxide generated by MitoPQ is rapidly converted to 
hydrogen peroxide, which crosses mitochondrial membranes and generates other reactive 
species that induce widespread oxidative damage (Murphy, 2009; Sena and Chandel, 
2012; Willems et al., 2015). NAC may quench this widespread damage by being a source 
of sulfhydryl groups that scavenge free radicals and protect protein disulfide bonds 
(Elbini Dhouib et al., 2016; Samuni et al., 2013).
These results show that the Parkinson’s like phenotypes induced by MitoPQ in 
zebrafish can be partially ameliorated by the indicated pharmacological strategies 
(antioxidant and monoaminergic potentiation), highlighting the potential of MitoPQ as a 
tool for in vivo redox biology research. We next decided to test MitoPQ in another 
experimental model of disease.
3.4. MitoPQ increases huntingtin aggregation in a cell model of Huntington’s disease
Given that treatment with MitoPQ generated a parkinsonian phenotype in zebrafish, 
which may also be interpreted as accelerated ageing (Collier et al., 2011), we decided to 
test how treatment with MitoPQ affects survival of a cell model of Huntington’s disease 
(HD) and the proteostasis of the disease associated protein – huntingtin (Htt). As with 
PD, HD pathophysiology includes mitochondrial dysfunction (Guedes-Dias et al., 2016) 
and age-dependent neurodegeneration (Lee and Kim, 2006). HD progresses with 
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increased formation of mutant Htt aggregates that evoke a slow, necrotic death (Ramdzan 
et al., 2017).
To model HD, we used U2OS cells expressing GFP-tagged wild-type (Q23) or 
mutant (Q74) Htt constructs, in OXPHOS-dependent conditions (galactose media), and 
treated with MitoPQ for 24 h. Solvent alone and rotenone were used for comparison with 
the effects of MitoPQ. Concentrations of 30 µM MitoPQ and 1 µM rotenone produced 
similar effects on metabolism in OXPHOS-dependent conditions (Fig. 1 A vs. C). Under 
control conditions, cells expressing Q23-Htt showed a diffuse GFP distribution with no 
detectable aggregates (Fig. 5A). In contrast, cells expressing Q74-Htt showed aggregates 
and a significantly higher cell death than Q23-Htt cells (Fig. 5B). Treatment with MitoPQ 
increased Q74-Htt aggregation without increasing cell death in cells expressing Q23- or 
Q74-Htt. This differs from treatment with rotenone where we observed a significant 
increase in cell death, particularly in cells expressing Q23-Htt. 
How might MitoPQ promote mHtt aggregation? While H2O2 diffusion from 
MitoPQ-challenged mitochondria might modify mHtt directly, promoting its aggregation 
(Kumar and Ratan, 2017), particularly near mitochondria (Fig. 6A), there is currently 
more evidence for indirect effects of ROS via impairments in the proteostasis machinery 
(Fig. 6C). Oxidative stress was found to promote mHtt aggregation in association with 
proteasomal dysfunction (Goswami et al., 2006) and, particularly, mitochondria-derived 
ROS was found to reduce the activity of the ubiquitin-proteasome system (Segref et al., 
2014; D’Amico et al., 2017). Additionally, mitochondria-derived ROS might promote 
mHtt aggregation by compromising the activity of molecular chaperones, which are 
vulnerable to ROS-mediated oxidation (Sorolla et al., 2012).
These results indicate that the use of MitoPQ as a co-stressor, to accelerate disease 
phenotypes, has advantages over classical mitochondrial inhibitors such as rotenone, 
namely by avoiding cell death under control conditions. Further, these results suggest that 
MitoPQ is an interesting tool to study the effects of increased mitochondrial superoxide 
production on huntingtin proteostasis, and possibly that of other mutant proteins in 
disease models. 
It is important to note that neurodegenerative disorders are associated with 
decreased mitochondrial membrane potential (Chaturvedi and Beal, 2013). Since MitoPQ 
uptake into mitochondria depends on mitochondrial membrane potential, it may be more 
useful in models of early stage disease where mitochondrial membrane potential is still 
maintained at normal levels. In our experimental conditions, at the time of treating with 
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MitoPQ, cells expressing either diffuse or aggregated mHtt retained mitochondrial 
membrane potential (TMRM+ staining) and were net ATP generators (oligomycin 
hyperpolarization) (Fig. 6B). As with other drugs or probes influenced by mitochondrial 
membrane potential (Polster et al., 2015), the mitochondrial polarization status should 
thus be taken into consideration when using MitoPQ.
4. Conclusions
The generation of mitochondrial superoxide plays an important role in ROS signalling 
and oxidative damage, but the lack of strategies for its selective generation have limited 
advancement in this field of research. The mitochondrial superoxide generator MitoPQ 
was recently developed as a tool to overcome this limitation, and here we present its first 
in vivo study in a vertebrate model. MitoPQ induces a parkinsonian phenotype in 
zebrafish larvae, supporting a contribution of mitochondrial superoxide generation to the 
development of PD. MitoPQ also led to an increase in mutant huntingtin aggregation in 
a cell model. These data suggest that MitoPQ can accelerate ageing-associated processes 
in vivo and in cell models.  MitoPQ is thus an interesting co-stressor to accelerate disease 
phenotypes, and a valuable tool to investigate the role of mitochondrial superoxide 
generation in physiological and pathological processes, using cellular and in vivo models.
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Figure Legends
Figure 1. Drug effects on cell metabolism and zebrafish survival.  (A) Resazurin 
metabolism of U2OS cells grown in glucose media (glycolytic conditions) and galactose 
media (OXPHOS-dependent conditions), after 24 h of treatment with increasing 
concentration of mitochondrial inhibitors: (i) rotenone – complex I inhibitor, (ii and iii) 
myxothiazol and antimycin – complex III inhibitors; and (iv) oligomycin – ATP synthase 
inhibitor; n = 3-4 independent experiments. (B) Resazurin metabolism of U2OS cells in 
glucose versus galactose media after treatment with MitoPQ and paraquat (left); and their 
chemical structures (right). Note that the decyl triphenylphosphonium lipophilic cation 
moiety targets MitoPQ to polarized mitochondria, and that MitoPQ was 100-fold more 
potent than paraquat in galactose media; n=3 independent experiments, *P< 0.05. (C) 
Kaplan-Meier survival analysis of zebrafish larvae exposed to MitoPQ (i), paraquat (ii), 
or solvent (control), n=24-50 larvae; and respective median survival times (iii).  
Figure 2. Behavioral, functional and biochemical parameters in zebrafish treated 
with MitoPQ vs. Paraquat. Zebrafish were treated with the indicated concentrations of 
MitoPQ and paraquat, or solvent (control), from 3 dpf until measurements (at 5 or 6 dpf). 
(A, B) Sensorimotor reflexes and spontaneous movement at 5 dpf: (Ai) tail and (Aii) head 
reflexes; (Bi) representative trajectories; (Bii) distance; (Biii) initiations, and (Biv) 
movement speed; n=27-78 larvae; *P<0.05 vs. control. (C) Protein carbonyl groups 
measured by dot-blot at 5 dpf. n=3 independent experiments, *P< 0.05 vs. control. (D) 
Left – energy charge values, calculated with the indicated formula, at 5 dpf (triangles) 
and 6 dpf (circles); Right – representative HPLC chromatogram with adenine nucleotides; 
n=3-4 independent experiments. (E) Heart rate and atrioventricular coordination at 6 dpf; 
n=16-19 larvae.
Figure 3. Brain levels of acetylated--tubulin and tyrosine hydroxylase (TH) in 
zebrafish treated with MitoPQ vs. paraquat. Larvae were treated from 3 to 5 dpf with 
10 µM MitoPQ, 1 mM paraquat, or solvent (control). Acetylated--tubulin and TH were 
quantified by immunofluorescence at 5 dpf. (A) Representative images and quantification 
of acetylated--tubulin in the midbrain; n=7-11 larvae, *P< 0.05 vs. control. (B) 
Representative images of TH-positive neurons and quantification of TH levels in (i) the 
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pretectum, (ii) middle diencephalon and (iii) hypothalamus. The first column shows 
global TH staining in blue, with a yellow highlight for the region under analysis; n=16-
18 larvae, *P < 0.05 vs. control.  
Figure 4. Effects of N-acetyl-L-cystein and desipramine on the behavioral and 
neurochemical phenotypes of MitoPQ-treated larvae. Larvae were treated from 3 to 5 
dpf with solvent (control), 10 µM MitoPQ, 1 mM N-acetyl-L-cystein (NAC), or 10 µM 
desipramine, alone or in the indicated combinations. (A) Sensorimotor reflexes at 5 dpf; 
(B) Spontaneous swimming distances at 5 dpf; n=19-54 larvae. (C) Representative 
acetylated--tubulin immunofluorescence in the midbrain and its quantification; n=7-11 
larvae. (D) Representative tyrosine hydroxylase immunofluorescence showing neuronal 
clusters in the pretectum and associated quantifications; n=13-18 larvae. *P< 0.05 vs. 
control; #P< 0.05 vs. MitoPQ 
Figure 5. Effects of MitoPQ on huntingtin proteostasis and cell viability in a HD cell 
model. U2OS cells transfected with GFP-Httex1Q23 or GFP-Httex1Q74 were treated for 
24 h with 30 µM MitoPQ, 1 µM rotenone, or solvent (control). (A) Huntingtin expression 
(EGFP) and nucleus staining (Hoechst 34580). Representative images show cells with 
Htt in diffuse form (Q23 and Q74) and Htt aggregates (observed only with Q74). (B) 
Quantification of live cells presenting (i) only diffuse huntingtin or (ii) containing 
aggregates; and (iii) cell death. n=6 independent experiments, *P< 0.05 vs. Q23; #P< 0.05 
vs. Q74.  
Figure 6. Mitochondria and ROS-mediated impairment of huntingtin proteostasis. 
(A) Representative U2OS cells expressing diffuse (left) and aggregated (right) mHtt-
EGFP (green) in proximity of TMRM+-stained mitochondria (red). (B) Representative 
tracings of changes in TMRM+ fluorescence of U2OS cells exposed to the indicated 
drugs: O, 6 µM oligomycin; R, 2 µM rotenone; A, 2 µM antimycin A; C, 2 µM CCCP; 
(i) non-transfected cell; (ii) cell expressing mHtt-EGFP, 24h-post transfection; tracings 
are representative of at least 10 cells per condition. (C) Mitoparaquat promotes 
mitochondria superoxide formation (Robb et al., 2015), arguably accelerating a process 
that is also thought to occur in the presence of mutant huntingtin (mHtt; Puranam et al., 
2006; Wang et al., 2013). Mitochondria-derived reactive-oxygen species (ROS) impair 
the ubiquitin-proteasome system (Goswami et al., 2006; Segref et al., 2014; D’Amico et 
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al., 2017), and may also impair chaperones (Sorolla et al., 2012; Kumar and Ratan 2017), 
limiting mHtt degradation and thereby promoting its accumulation and aggregation. 
Increased levels of mHtt promote its interaction with mitochondria, and ROS formation 
(Puranam et al., 2006; Wang et al., 2013). Such ROS, together with those generated from 
mHtt aggregation (Hands et al., 2011) may modify mHtt directly, further promoting its 
aggregation (Kumar and Ratan 2017).








